UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

———————

ü	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
	ACT OF 1934
For the quarterly period ended: September 30, 2008
or
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
	ACT OF 1934
For the transition period from: _____________ to _____________

Commission File Number: 000-50746

———————

CORD BLOOD AMERICA, INC.

(Exact name of registrant as specified in its charter)

———————

FLORIDA	65-1078768
(State or other jurisdiction	(I.R.S. Employer
of incorporation or organization)	Identification No.)

501 SANTA MONICA BLVD. STE. 700, SANTA MONICA, CA 90401

(Address of Principal Executive Office) (Zip Code)

(310) 432-4090

(Registrant’s telephone number, including area code)

———————

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.			ü	Yes		No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
Large accelerated filer		Accelerated filer
Non-accelerated filer	(Do not check if a smaller	Smaller reporting company			ü
	reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
				Yes	ü	No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.   As of November 10, 2008, there were 309,474,243 shares of the registrant’s Common Stock outstanding.
APPLICABLE ONLY TO CORPORATE ISSUERS:
Transitional Small Business Disclosure format (check one):				Yes	ü	No

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q

Page

PART I. FINANCIAL INFORMATION

PART II. OTHER INFORMATION

PART I. FINANCIAL INFORMATION

ITEM 1.

CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET (UNAUDITED)
AS OF SEPTEMBER 30, 2008 AND DECEMBER 31, 2007

ASSETS
Current assets:	September 30, 2008			December 31, 2007
Cash	$	56,599		$	338,828
Accounts receivable, net of allowance for doubtful accounts of $35,000		39,514			92,559
Supplies		5,345			5,345
Prepaid expenses		14,250			67,544
Total current assets		115,708			504,276
Property and equipment, net of accumulated depreciation and amortization of $272,695 and $204,806		70,481			138,370
Deferred financing costs		788,954			1,210,109
Customer contracts and relationships, net of amortization of $809,813 and $438,533		4,496,309			4,868,967
Deposits		20,130			10,683
Domain name, net of amortization of $104 and $73		295			326
Other assets		670			670
Total assets	$	5,492,547		$	6,733,401
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	1,072,810		$	999,393
Accrued expenses		2,121,378			1,830,809
Deferred revenue		1,100,508			1,043,260
Wages owing to Officers		112,364			––
Advances from Officers		136,893			188,955
Capital lease obligations		1,982			3,734
Derivatives Liability		1,961,878			1,309,854
Promissory notes payable, net of unamortized discount of $2,058,218 and $4,086,914		6,308,034			4,523,533
Total current liabilities		12, 815,847			9,899,538
Stockholders’ deficit:
Preferred stock, $.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding		––			––
Common stock, $.0001 par value, 950,000,000 shares authorized, 276,305,431 and 195,558,923 shares issued and outstanding, inclusive of treasury shares		27,630			19,569
Additional paid-in capital		28,178,497			31,985,408
Common stock held in treasury stock, 41,266,667 and 46,266,667 shares		(12,159,833	)		(17,159,833	)
Accumulated deficit		(23,369,594	)		(18,011,281	)
Total stockholders’ deficit		(7,323,300	)		(3,166,137	)
Total liabilities and stockholders’ deficit	$	5,492,547		$	6,733,401

See the accompanying notes to condensed consolidated financial statements.

1

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

	NINE-MONTH PERIOD			NINE-MONTH PERIOD
	ENDED			ENDED
	SEPTEMBER 30,			SEPTEMBER 30,
	2008			2007
Revenue	$	3,329,120		$	5,697,701
Cost of services		(1,522,101	)		(3,313,701	)
Gross profit		1,807,019			2,384,000
Administrative and selling expenses		(2,833,896	)		(3,659,485	)
Loss from Operations		(1,026,877	)		(1,275,485	)
Interest expense and change in derivative liability		(4,332,317	)		(2,912,393	)
Net loss before income taxes		(5,359,194	)		(4,187,878	)
Income taxes		––			––
Net loss		(5,359,194	)		(4,187,878	)
Basic and diluted loss per share	$	(0.02	)	$	(0.05	)
Weighted average common shares outstanding		232,263,129			88,278,103

See the accompanying notes to condensed consolidated financial statements.

2

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

	THREE-MONTH PERIOD			THREE-MONTH PERIOD
	ENDED			ENDED
	SEPTEMBER 30,			SEPTEMBER 30,
	2008			2007
Revenue	$	927,359		$	1,654,494
Cost of services		(449,937	)		(660,045	)
Gross profit		477,422			994,449
Administrative and selling expenses		(942,045	)		(1,061,531	)
Loss from Operations		(464,623	)		(67,082	)
Interest expense and change in derivative liability		(1,146,019	)		(1,040,892	)
Net loss before income taxes		(1,610,642	)		(1,107,974	)
Income taxes		––			––
Net loss		(1,610,642	)		(1,107,974	)
Basic and diluted loss per share	$	(0.01	)	$	(0.01	)
Weighted average common shares outstanding		258,075,887			114,319,626

See the accompanying notes to condensed consolidated financial statements.

3

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

	NINE-MONTH			NINE-MONTH
	PERIOD ENDED			PERIOD ENDED
	SEPTEMBER 30,			SEPTEMBER 30,
	2008			2007
Cash flows from operating activities:
Net loss	$	(5,359,194	)	$	(4,187,878	)
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of stock for services		675,055			761,694
Gain on exercise of warrants		(150,007	)		––
Amortization of loan discount		2,090,484			2,190,508
Amortization of shares issued for services		––			262,522
Amortization of deferred financing costs		421,155			––
Depreciation and amortization		440,579			622,594
Change in value of derivative liability		1,019,611			––
Share based compensation		––			15,559
Net change in operating assets and liabilities		651,909			343,136
Net cash used in (provided by) operating activities		(210,408	)		8,135
Cash flows from investing activities:
Purchase of CorCell		––			(239,085	)
Proceeds from Escrow		––			150,000
Purchase of CureSource		––			(106,500	)
Purchase of property and equipment					(2,937	)
Net cash provided by investing activities		––			(198,522	)
Cash flows from financing activities:
Repayments on loans payable		(584,216	)		(668,487	)
Proceeds from advances from officers		15,538			223,725
Issuance of common shares for cash		287,981			275,305
Proceeds from issuance of notes payable		278,228			450,000
Payments on capital lease obligations		(1,750	)		(4,379	)
Payments on advances from officers		(67,600	)		––
Net cash provided by (used in) financing activities		(71,819	)		276,164
Net increase (decrease) in cash		(282,227	)		85,777
Cash and cash equivalents, at beginning of period		338,828			21,566
Cash and cash equivalents, at end of period	$	56,599		$	107,343

See the accompanying notes to condensed consolidated financial statements.

4

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

	NINE-MONTH		NINE-MONTH
	PERIOD ENDED		PERIOD ENDED
	SEPTEMBER 30,		SEPTEMBER 30,
	2008		2007
Supplemental disclosures of cash flow information:
Cash paid for interest	$	102,506	$	173,540
Supplemental disclosures of non-cash investing and financing activities:
Shares issued for the purchase of CureSource		––		10,000
Discount on issuance of debt with detachable warrants		––		4,845,000
Shares issued for future services		––		1,418,365
Shares issued for the acquisition of CorCell business		––		1,761,077
Debt repaid through issuance of common stock	$	25,000	$	822,916

See the accompanying notes to condensed consolidated financial statements.

5

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2008

Note 1. Organization and Description of Business

Cord Blood America, Inc. ("CBAI"), formerly D&A Lending, Inc., was incorporated in the State of Florida on October 12, 1999. CBAI's headquarters are located in Los Angeles, California. CBAI is primarily a holding company whose subsidiaries include Cord Partners, Inc., CorCell Co. Inc., CorCell Ltd., (“Cord”), CBA Professional Services, Inc. D/B/A BodyCells, Inc. ("BodyCells"), CBA Properties, Inc. ("Properties"), and Career Channel Inc, D/B/A Rainmakers International ("Rain"). CBAI and its subsidiaries engage in the following business activities:

·

Cord specializes in providing private cord blood stem cell preservation services to families.

·

BodyCells is a developmental stage company and intends to be in the business of collecting, processing and preserving peripheral blood and adipose tissue stem cells allowing individuals to privately preserve their stem cells for potential future use in stem cell therapy.

·

Properties was formed to hold the corporate trademarks and other intellectual property of CBAI.

·

Rain specializes in creating direct response television and radio advertising campaigns, including media placement and commercial production.

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that may be necessary in the event CBAI cannot continue as a going concern.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements of Cord Blood America, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with Article 8 of Regulation S-X . Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The consolidated financial statements reflect all normal recurring adjustments, which, in the opinion of management, are considered necessary for a fair presentation of the results for the periods shown. The results of operations for the periods presented are not necessarily indicative of the results expected for the full fiscal year or for any future period. Certain prior period amounts have been reclassified to conform to the current period presentation. The information included in these unaudited consolidated financial statements should be read in conjunction with Management's Discussion and Analysis and Plan of Operations contained in this report and the audited consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007.

Basis of Consolidation

The consolidated financial statements include the accounts of CBAI and its wholly owned subsidiaries, Cord, CorCell Co, CorCell Ltd., BodyCells, Properties and Rain. Significant inter-company balances and transactions have been eliminated upon consolidation.

Deferred Revenue

Deferred revenue for Cord consists of payments for enrollment in the program and processing of umbilical cord blood by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year. Deferred revenue for Rain consists of payments for per inquiry leads that have not yet been delivered or media buys that have not yet been placed.

Valuation of Derivative Instruments

SFAS No. 133 “Accounting for Derivative Instruments and Hedging Activities” requires that embedded derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with EITF 00-19 “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock” to determine whether they should be considered a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula. At September 30, 2008, the Company adjusted its derivative liability to its fair value, and reflected the decrease in fair value, in its statement of operations, as a reduction of interest expense.

6

Revenue Recognition

CBAI recognizes revenue under the provisions of Staff Accounting Bulletin ("SAB") 104 "Revenue Recognition". Cord provides a combination of products and services to customers. This combination arrangement is evaluated under Emerging Issues Task Force (Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables," ("EITF 00-21"). EITF 00-21 addresses certain aspects of accounting for arrangements under multiple revenue generating activities. CBAI elected early adoption of EITF 00-21.

Cord Blood recognizes revenue from both enrollment fees and processing fees upon the completion of processing. Storage fees are recognized ratably over the contractual storage period, unless the customer enrolls in the Annual Payment Option.

Rain generates revenue from packaged advertising services, including media buying, marketing and advertising production services. Rain's advertising service revenue is recognized when the media ad space is sold and the advertising occurs. Rain's advertising production service revenue is derived through the production of an advertising campaign including, but not limited to, audio and video production, establishment of a target market and the development of an advertising campaign. Rain recognizes revenue generated from packaged advertising services provided to our clients using the "Gross" basis of Emerging Issues Task Force No. 99-19, "Reporting Revenue Gross as a Principal versus Net as an Agent" (EITF 99-19).

Rain's revenue recognition policy involves significant judgments and estimates about the ability to collect. We assess the probability of collection based on a number of factors, including past transaction history and/or the creditworthiness of our clients' customers, which is based on current published credit ratings, current events and circumstances regarding the business of our client's customer and other factors that we believe are relevant. If we determine that collection is not reasonably assured, we defer revenue recognition until such time as collection becomes reasonably assured, which is generally upon receipt of cash payment. Rain recognizes revenue generated through per inquiry advertising as the inquiry leads are delivered to the customer.

Cost of Services

Costs for Cord are incurred as umbilical cord blood is collected. These costs include the transport of the umbilical cord blood from the hospital to the lab, the labs processing fees, and royalties. Cord expenses costs in the period incurred and does not defer any costs of sales. Costs for Rain include commercial productions costs, lead generation costs and media buys.

Net Loss Per Share

Net loss per common share is calculated in accordance with SFAS No. 128, Earnings per Share. Basic net loss per share is computed by dividing the net loss by the weighted average common shares outstanding of 232,263,129 and 88,278,103 for the nine-months ended September 30, 2008 and 2007, respectively. Outstanding options to acquire common stock and warrants are not included in the computation of net loss per common share because the effects of inclusion are anti-dilutive.

Recent Accounting Pronouncements

In September 2006, the FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 157, Fair Value Measurements (“SFAS No. 157”). SFAS No. 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 does not expand the use of fair value in any new circumstances. In February 2008, the FASB issued Staff Position No. FAS 157-1, which amended SFAS No. 157 to exclude SFAS No. 13, Accounting for Leases, and other accounting pronouncements that address fair value measurements for purposes of lease classification or measurement under Statement 13. However, this scope exception does not apply to assets acquired and liabilities assumed in a business combination. Also in February 2008, the FASB issued Staff Position No. FAS 157-2, which delayed the effective date of SFAS No. 157 for non-financial assets and liabilities, except those items recognized at fair value on an annual or more frequently recurring basis to fiscal years beginning after November 15, 2008 and interim periods within those fiscal years.  Adoption of SFAS No. 157 did not have a significant impact on the Company’s consolidated financial statements. In October 2008, the FASB issued Staff Position No. 157-3, to clarify the application of SFAS No. 157 when the market for a financial asset is inactive. The Company adopted SFAS No. 157 with no material impact on the Company’s consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, Fair Value Option for Financial Assets and Financial Liabilities (“SFAS No. 159”). SFAS No. 159 permits entities to choose to measure many financial assets and financial liabilities at fair value. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. Adoption of SFAS No. 159 did not have a significant impact on the Company’s consolidated financial statements.

In June 2007, the FASB ratified the consensus on Emerging Issues Task Force (“EITF”) Issue No. 06-11, Accounting for Income Tax Benefits of Dividends on Share-Based Payment Awards (“EITF 06-11”). EITF 06-11 requires companies to recognize the income tax benefit realized from dividends or dividend equivalents that are charged to retained earnings and paid to employees for non-vested equity-classified employee share-based payment awards as an increase to additional paid-in capital. EITF 06-11 is effective for fiscal years beginning after September 15, 2007. The adoption did not have a significant impact on the Company’s consolidated financial statements.

7

In June 2007, the FASB ratified the consensus reached on EITF Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities (“EITF 07-3”), which requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. EITF 07-3 will be effective for fiscal years beginning after December 15, 2007. The adoption of EITF 07-3 did not have an impact on the Company’s consolidated financial statements.

In December 2007, the FASB issued SFAS No. 160, Non-controlling Interests in Consolidated Financial Statements (“SFAS No. 160”) and a revision to SFAS No. 141, Business Combinations (“SFAS No. 141R”). SFAS No. 160 modifies the accounting for non-controlling interest in a subsidiary and the deconsolidation of a subsidiary. SFAS No. 141R establishes the measurements in a business combination of the identifiable assets acquired, the liabilities assumed and any non-controlling interest in the acquiree. Both of these related statements are effective for fiscal years beginning after December 15, 2008. Currently, the Company does not expect the adoption of SFAS No. 161 will have an impact on our consolidated financial statements.

In December 2007, the SEC issued Staff Accounting Bulletin 110 (“SAB 110”), which expresses the views of the Staff regarding use of a “simplified” method, as discussed in SAB 107, in developing an estimate of expected term of “plain vanilla” share options in accordance with Statement of Financial Accounting Standards No. 123R. SAB 110 will allow, under certain circumstances, the use of the simplified method beyond December 31, 2007 when a Company is unable to rely on the historical exercise data.

In March 2008, the Financial Accounting Standards Board or FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities,” which amends SFAS No. 133. The statement is intended to improve transparency in financial reporting by requiring enhanced disclosures of an entity’s derivative instruments and hedging activities and their effects on the entity’s financial position, financial performance, and cash flows. SFAS 161 is effective prospectively for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. Currently, the Company does not expect the adoption of SFAS No. 161 will have an impact on our consolidated financial statements.

In April 2008, the FASB issued Staff Position No. FAS 142-3, Determination of the Useful Life of Intangible Assets, which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under FASB Statement No. 142, “Goodwill and Other Intangible Assets.”  The Position is effective for fiscal years beginning after December 15, 2008 and only applies prospectively to intangible assets acquired after the effective date.  Early adoption is not permitted.  The Company is currently evaluating the impact this statement will have on our results of operations and financial position.

In May 2008, the FASB issued Staff Position No. Accounting Principles Board 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) (“FSP No. APB 14-1”).  FSP No. APB 14-1 requires that the liability and equity components of convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) be separately accounted for in a manner that reflects an issuer’s nonconvertible debt borrowing rate.  FSP No. APB 14-1 is effective for us as of January 1, 2009.  The Company is evaluating the impact this change will have on our consolidated financial statements.

Going Concern

CBAI's consolidated financial statements have been prepared assuming it will continue as a going concern. CBAI has experienced recurring net losses from operations, which losses have caused an accumulated deficit of approximately $23.4 million as of September 30, 2008. In addition, CBAI has a working capital deficit of approximately $12.7 million as of September 30, 2008. These factors, among others, raise substantial doubt about CBAI's ability to continue as a going concern.

Management has been able, thus far, to finance the losses and the growth of the business, through private placements of its common stock, the issuance of debt and proceeds from the Equity Distribution Agreement, the Shelter Securities Purchase Agreement and the Enable Securities Purchase Agreement. CBAI is continuing to attempt to increase revenues within its core businesses. In addition, CBAI is exploring alternate ways of generating revenues through acquiring other businesses in the stem cell industry.  In June, 2008, the Company announced the signing of a Securities Purchase Agreement with Tangiers Investors, LP, whereby Tangiers may purchase up to $4 million of the Company’s common stock. The Company filed a registration statement to register certain shares of common stock issuable pursuant to the Securities Purchase Agreement. The Securities and Exchange Commission declared the Registration Statement effective on November 4, 2008. As well, the Company has taken steps to reduce its overall spending through the reduction of headcount and cuts in sales and administrative expenses. The ongoing execution of CBAI's business plan is expected to result in operating losses over the next twelve months. There are no assurances that CBAI will be successful in achieving its goals of increasing revenues and reaching profitability.

8

In view of these conditions, CBAI's ability to continue as a going concern is dependent upon its ability to meet its financing requirements, and to ultimately achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event CBAI cannot continue as a going concern.

Reclassification of Expenses

The Company has re-classed some of its expenses in the comparative Consolidated Statement of Operations to conform to the current presentation.

Note 3.  Accrued Expenses

The components of accrued expenses at September 30, 2008 are summarized as follows:

	September 30,
	2008
Accrued interest and related financing expenses	$	1,986,673
Deferred Rent		24,339
Other		110,366
	$	2,121,378

Note  4. Notes and Loans Payable

Shelter Island Opportunity Fund

In February 2007, the company contracted a note payable in the amount of $2,300,000. In connection with the agreement, the note holder was issued warrants to purchase shares of the Company at $0.037 per share. In March 2008, the Company  reduced the conversion price to $0.0086 per share, provided the warrant was exercised in March, 2008. This offer was extended through the end of July, 2008. In May, 2008, Shelter exercised 20,270,270 warrants and received 2,837,238 shares on a cashless basis.

Enable Capital

In November 2007, the Company contracted a 0% convertible debenture with Enable Capital for a face amount of $1,931,106, and net proceeds of $1,369,000. The note is convertible at $0.03 per share or 96% of market price as defined. The Company used $544,000 of the proceeds to pay down its accrued interest to Cornell. In connection with this convertible note, the Company issued a warrant to purchase 48,277,655 shares of the Company's common stock at an exercise price of $0.037 per share. In March 2008, the Company offered the warrant holders to reduce the conversion price to $0.0086 per share, if exercised in March, 2008. This offer was extended through the end of July, 2008. Warrant holders exercised warrants and purchased 30,370,553 shares at $0.0086. This was treated as an inducement to exercise, and it resulted in a gain of $150,007, as the value of the related derivative liability was higher than the value of the modified warrants at the date of exercise. On May 30, 2008, due to anti-dilution provisions, the Company issued warrants to Enable Capital to purchase 9,655,531 Common Shares at $0.0086 per share, leaving Enable with a balance of 27,562,663 warrants to purchase the Company’s common stock at September 30, 2008.

Note  5. Commitments and Contingencies

Agreements

Progenitor Cell Therapy, LLC - The Company entered into an agreement on August 1, 2007, with Progenitor Cell Therapy, LLC (PCT) to process, test and store all umbilical cord blood samples collected.  The agreement has a five year term and contains termination provisions for each party.  

Pharmastem

In March 2004, Cord entered into a Patent License Agreement with the holder of patents utilized in the collection, processing, and storage of umbilical cord blood to settle litigation against Cord for alleged patent infringements. The

Patent License Agreement calls for royalties of 15% of processing and storage revenue, with a minimum royalty of $225 per specimen collected, on all specimens collected after January 1, 2004 until the patents expire in 2010.

Employment Agreements

On July 16, 2008, CBAI entered into a one-year employment agreement with Matthew L. Schissler (the "Executive Agreement"). Pursuant to his Executive Agreement, Mr. Schissler serves as Chairman and Chief Executive Officer of CBAI at an annual salary of $165,000 through July 14, 2009. The Executive Agreement entitles Mr. Schissler to receive a performance bonus of up to 30% of his salary, as well as certain other benefits, including stock options. Mr. Schissler is subject to non-competition and confidentiality

9

requirements. This agreement will automatically be renewed for a period of two years, with an increase in base salary of 5%. CBAI also entered into a one-year employment agreement with Mr. Joe Vicente. Pursuant to his Agreement, Mr. Vicente serves as Vice President of CBAI at an annual salary of $115,000 through July 14, 2009. The Executive Agreement entitles Mr. Vicente to receive a performance bonus of up to 25% of his salary, as well as certain other benefits, including stock options. Mr. Vicente is subject to non-competition and confidentiality requirements. This agreement will automatically be renewed for a period of two years, with an increase in base salary of 5%.

Compensation of the Board of Directors

On January 26, 2006, CBAI's Board of Directors approved a Board Compensation Plan (the “Plan”) effective through 2008. The Plan called for shares of the Company’s common stock to be issued as compensation for the second year of service in 2007 and 2008 in an amount equal to $10,000.

Note 6. Related Party Transactions and Commitments

Advances from Officers

In prior years, the Company received non-interest bearing advances from officers of CBAI. During the three months ended March 31, 2008, the Company repaid in full these advances. In addition, on May 11, 2007, Ms. Stephanie Schissler, CBAI's former President and Chief Operating Officer, who is the spouse of the Company's Chief Executive Officer, loaned $121,500 to the Company, to be repaid in 36 equal monthly installments of $3,908. The Company signed a Promissory Note, which carries interest at the rate of 10% per annum. At September 30, 2008, the balance remaining on this loan was $74,627.

On June 14, 2007, Mr. Matt Schissler, the Company’s Chief Operating Officer, loaned $25,650 to the Company, to be repaid in 36 equal monthly installments of $828. The Company signed a Promissory Note, which carries interest at the rate of 10% per annum. At September 30, 2008, the balance remaining on this loan was $16,362.

On June 14, 2007, Ms. Stephanie Schissler loaned a further $76,950 to the Company, to be repaid in 36 equal monthly installments of $2,483. The Company signed a Promissory Note, which carries interest at the rate of 10% per annum. At September 30, 2008, the balance remaining on this loan was $49,091.

On January 25, 2008, Ms. Stephanie Schissler loaned a further $9,400 to the Company; repayment terms have not yet been worked out between the parties.

On April 1, 2008, Ms. Stephanie Schissler loaned a further $6,138 to the Company; repayment terms have not yet been worked out between the parties.

In addition, Mr. Matt Schissler and Mr. Joe Vicente, officers of the Company, have deferred receipt of a portion of their salaries, totaling $112,364 at September 30, 2008.

Consulting Agreement

On July 1, 2008, CBAI entered into a one-year consulting agreement with Stephanie Schissler, The agreement entitles Ms. Schissler to a $11,500 per month retainer and stock option incentives for her services in relation to strategic corporate planning and other business related matters. The agreement automatically renews, unless a 60-day written notice of cancellation is provided by either CBAI or Ms. Schissler.

Note 7. Share Based Compensation

Stock Option Plan

The Company's Stock Option Plan permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20.0 million shares of its common stock. The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company.

Stock options that vest at the end of a one-year period are amortized over the vesting period using the straight-line method. For stock options awarded using graded vesting, the expense is recorded at the beginning of each year in which a percentage of the options vests.

10

At September 30, 2008, the Company’s stock option activity was as follows:

	Stock Options		Weighted Average Exercise Price
Outstanding, January 1, 2008		5,808,140	$	0.26
Granted		17,500,000	$	0.01
Exercised		0
Forfeited/Expired		0
Outstanding, September 30, 2008		23,308,140	$	0.07
Exercisable at September 30, 2008		9,308,140	$	0.16

A summary of the activity for unvested employee stock options as of September 30, 2008, and changes during the year are presented below:

	Stock Options			Weighted Average Grant Date Fair Value per Share
Nonvested at January 1, 2008		765,000		$	0.17
Granted		17,500,000			––
Vested		(4,265,000	)	$	0.01
Forfeited		0			––
Nonvested at September 30, 2008		14,000,000		$	0.01

The following table summarizes significant ranges of outstanding stock options under the stock option plan at September 30, 2008:

Range of Exercise Prices		Number of Options		Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price		Number of Options Exercisable		Weighted Average Contractual Life	Weighted Average Exercise Price
$	0.01 — 0.20		18,473,192	4.92	$	0.01		4,648,192	4.92	$	0.01
$	0.21 — 0.30		3,028,850	6.13		0.25		2,853,850	6.12		0.25
$	0.31 — 0.51		1,806,098	6.94		0.31		1,806,098	6.94		0.31
			23,308,140	5.23	$	0.07		9,308,140	5.23	$	0.07

Note 8. Warrant Agreements

On March 10, 2008, Enable Capital, a warrant holder, exercised their right to purchase 9,272,000 shares of the Company’s Common Stock at $0.0086 per share.

On April 7 and May 29, 2008 respectively, Enable Capital exercised their right to purchase 7,127,624 and 5,250,000 shares of the Company’s Common Stock at $0.0086 per share.

On May 30, 2008, due to anti-dilution provisions, the Company issued warrants to Enable Capital to purchase 9,655,531 Common Shares at $0.0086 per share. On the same date, Shelter Island exchanged their rights to purchase 20,270,270 Common Shares at $0.037 per share and received 2,837,838 common shares on a cashless basis.

On July 15, 2008, Enable Capital exercised their right to purchase 8,720,292 shares of the Company’s Common Stock at $0.0086 per share. The Company also has put options with Shelter Island and Ascendient, under which the Company could be required to repurchase 40,000,000 shares of its common stock at $0.05 per share.

The following table summarizes the warrants outstanding and exercisable at September 30, 2008:

WARRANTS OUTSTANDING		EXERCISE PRICE		MATURITY DATE
	1,000,000	$	0.1875	09/19/2009
	14,285,000	$	0.35	09/09/2010
	8,285,000	$	0.101	09/09/2010
	40,000,000	$	0.101	02/12/2012
	20,823,769	$	0.037	11/26/2012
	9,655,531	$	0.0086	05/30/2013
Total 94,049,300

11

Note 9. Stockholder’s Equity

Preferred Stock

CBAI has 5,000,000 shares of $.0001 par value preferred stock authorized. No preferred stock has been issued to date.

Common Stock

During the first nine months of 2008, the Company issued 2,633,588 common shares to certain of its employees and 1,764,705 common shares to its directors. It also issued 30,475,325 in exchange for services rendered and for the payment of certain accounts payable.

During the first nine months ending September 30, 2008, a warrant holder exercised a portion of their warrants, or 30,370,553 shares at the special exercise price of $0.0086, providing approximately $261,000 of cash.

In the first nine months of 2008, the Company issued 16.6 million common shares in relation to delays, changes or extensions in terms of loan financings. In addition, the Company reduced one of its outstanding debentures by $25,000 in exchange for the issuance of 3,731,343 common shares.

As of September 30, 2008 CBAI had 276,305,431 shares of Common Stock outstanding. An additional 41,266,667 shares has been issued and remains in the Company’s treasury.    

In the three month period ended September 30, 2008, the Company’s shareholders approved an increase in its authorized capital to 950,000,000 common shares.

On June 27, 2008, we entered into a Securities Purchase Agreement with Tangiers Investors, LP whereby Tangiers may purchase up to $4 million of the Company’s common stock. CBAI has filed a Registration Statement on Form S-1 to register a portion of the shares issuable pursuant to the Securities Purchase Agreement. The registration statement was declared effective on November 4, 2008.

Note 12. Segment Reporting

SFAS No. 131 "Disclosures about Segments of an Enterprise and Related Information," requires that public business enterprises report financial and descriptive information about its reportable operating segments. CBAI has two operating segments. Cord generates revenues related to the processing and preservation of umbilical cord blood. Rain generates revenues related to television and radio advertising. All of its long-lived assets are located in, and substantially all of its revenues are generated from within, the United States of America.

The table below presents certain financial information by business segment for the nine months ended September 30, 2008:

					Adipose/			Radio/
	Umbilical				Peripheral			Television			Segments				Consolidated
	Cord Blood				Blood			Advertising			Total				Total
Revenue from External Customers		$	2,623,463			$	0		$	705,657		$	3,329,120			$	3,329,120
Interest Expense			4,326,054				0			6,263			4,332,317				4,332,317
Depreciation and Amortization			440,578				0			0			440,578				440,578
Segment Income (Loss)			(5,560,284	)						201,090			(5,359,194	)			(5,359,194	)
Segment Assets		$	5,460,432			$	97		$	32,018		$	5,492,547			$	5,492,547

The table below presents certain financial information by business segment for the nine months ended September 30, 2007:

					Adipose/			Radio/
	Umbilical				Peripheral			Television			Segments				Consolidated
	Cord Blood				Blood			Advertising			Total				Total
Revenue from External Customers		$	3,079,919			$	0		$	2,617,782		$	5,697,701			$	5,697,701
Interest Expense			2,910,818				0			1,575			2,912,393				2,912,393
Depreciation and Amortization			374,089				0			0			374,089				374,089
Segment Income (Loss)			(4,421,592	)						233,714			(4,187,878	)			(4,187,878	)
Segment Assets		$	5,771,093			$	197		$	114,565		$	5,885,855			$	5,885,855

12

The table below presents certain financial information by business segment for the three months ended September 30, 2008:

					Adipose/			Radio/
	Umbilical				Peripheral			Television			Segments				Consolidated
	Cord Blood				Blood			Advertising			Total				Total
Revenue from External Customers		$	845,572			$	0		$	72,787		$	927,359			$	927,359
Interest Expense			1,143,628				0			2,391			1,146,019				1,146,019
Depreciation and Amortization			135,597				0						135,597				135,597
Segment Income (Loss)			(1,714,297	)						103,655			(1,610,642	)			(1,610,642	)
Segment Assets		$	5,460,432			$	97		$	32,018		$	5,492,547			$	5,492,547

The table below presents certain financial information by business segment for the three months ended September 30, 2007:

					Adipose/			Radio/
	Umbilical				Peripheral			Television			Segments				Consolidated
	Cord Blood				Blood			Advertising			Total				Total
Revenue from External Customers		$	1,211,023			$	0		$	443,471		$	1,654,494			$	1,654,494
Interest Expense			1,039,557				0			1,335			1,040,892				1,040,892
Depreciation and Amortization			151,550				0			0			151,550				151,550
Segment Income (Loss)			(1,071,858	)						(36,116			(1,107,974	)			(1,107,974	)
Segment Assets		$	5,771,093			$	197		$	114,565		$	5,885,855			$	5,885,855

13

Item 2. Management’s Discussion and Analysis

Forward Looking Statements

In addition to the historical information contained herein, we make statements in this Quarterly Report on Form 10-Q that are forward-looking statements. Sometimes these statements will contain words such as "believes," "expects," "intends," "should," "will," "plans," and other similar words. Forward-looking statements include, without limitation, our ability to increase income streams, to grow revenue and earnings, and to obtain additional cord blood banking revenue streams. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties.

The following information should be read in conjunction with our September 30, 2008 consolidated financial statements and related notes thereto included elsewhere in the quarterly report and with our consolidated financial statements and notes thereto for the year ended December 31, 2007 and the related "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in our annual Report on Form 10-KSB/A for the year ended December 31, 2007. We also urge you to review and consider our disclosures describing various risks that may affect our business, which are set forth under the heading "Risk Factors Related to our Business" in our annual Report on Form 10-KSB/A for the year ended December 31, 2007.

Summary and Outlook of the Business

CBAI is an umbilical cord blood stem cell preservation company with a particular focus on the acquisition of customers in need of family based products and services. We also provide television, radio and internet advertising services to businesses that sell family based products and services.  

We operate two core businesses:

·

Cord operates the umbilical cord blood stem cell preservation operations, and

Career Channel, Inc. D/B/A Rainmakers International ("Rain") operates the television and radio advertising operations.

Cord

The umbilical cord blood stem cell preservation operations provide umbilical cord blood banking services to expectant parents throughout all 50 United States. Our corporate headquarters are located in Los Angeles, CA. Cord also maintains offices in Philadelphia, Pennsylvania. Cord earns revenue through a one-time enrollment and processing fee, and through an annually recurring storage and maintenance fee. Cord blood testing, processing, and storage is conducted by our outsourced laboratory partner, formerly Bergen Community Regional Blood Services, located in Paramus, New Jersey. On August 1, 2007, CBAI entered into an agreement with Progenitor Cell Therapy, LLC, (PCT) for testing, processing and storage of cord blood samples.  The Company believes this transition from Bergen to PCT will provide additional leverage to operating costs and efficiencies while maintaining the highest of quality standards. We provide the following services to each customer. In addition, some storage services are provided by ThermoFisher of Rockville, Maryland.

·

Collection Materials. We provide a medical kit that contains all of the materials necessary for collecting the newborn’s umbilical cord blood at birth and packaging the unit for transportation. The kit also provides for collecting a maternal blood sample for later testing.

·

Physician And Customer Support. We provide 24-hour consulting services to customers as well as to physicians and labor and delivery personnel, providing any instruction necessary for the successful collection, packaging, and transportation of the cord blood & maternal blood samples.

·

Transportation. We coordinate the transportation of the cord blood unit to our laboratory partner, Progenitor Cell Therapies, immediately following birth. This process utilizes a private medical courier, Airnet, for maximum efficiency and security.

·

Comprehensive Testing. At the laboratory, the cord blood sample is tested for stem cell concentration levels, bacteria and blood type.  The maternal blood sample is tested for infectious diseases. We report these results to the newborn’s mother.

·

Cord Blood Preservation. After processing and testing, the cord blood unit is cryogenically frozen in a controlled manner and stored in liquid nitrogen for potential future use. Data indicates that cord blood retains viability and function for at least fifteen years when stored in this manner and theoretically could be maintained at least as long as the normal life span of an individual.

We believe Cord’s revenue and gross profit will benefit from the asset purchase of CorCell. Going forward, management will continue to assess the market conditions, particularly related to the cost of customer acquisition, and whether organic growth or continued M&A activity will lead CBAI closer to profitability.

14

Rain

Rain, the television, radio, on-hold and motor sports advertising operations, are located in the corporate headquarters in Los Angeles, CA. The offices were relocated from Carlsbad, CA in September 2006. Rain provides advertising and direct marketing customers a range of services including:

·

the placement of advertising in television, radio, on-hold and motor sports outlets;

·

the production of advertising content, including television commercials and radio copy, which is outsourced to third party production companies; and

·

advertising and marketing consulting services which can include assistance in not only developing an advertising program, but helping the client to develop the particular product or service, determine the appropriate market and design and implement an overall marketing program and strategy.

A majority of Rain's revenues are earned via direct response media buys and per inquiry campaigns. For direct response, we currently buy television and radio schedules for our clients on a national and local level. Our national television outlets include Directv, DISH Network, Comcast Digital, national cable networks and various local cable interconnects. We buy time with numerous national radio networks including Premiere Radio, Clear Channel, Westwood One and Jones Radio Network, along with a variety of local radio stations. For per inquiry advertising, we focus on national campaigns. The placements are made using our internal media buyers and other agencies with which we have formed strategic marketing alliances. We also generate revenues through the commercial production aspect of our business using production partners in Florida and California.  Our on-hold advertising is placed on a client’s telephone system.  Production is outsourced to AudioMenu of Fort Lauderdale, FL.  Motor sports sponsorship is placed on vehicles in various motor sports circuits.  Most advertising has been placed with BAM Racing, LLC.  In January of 2008 we entered in a non-exclusive agreement with BAM Racing, LLC.  The agreement compensates for sales of sponsorship of NASCAR Sprint Cup Team #49.

In December, 2007, Rain made a significant shift in its business development strategy.  Rain’s revenues prior to 2008 were largely reliant on a few customers.  Rain decided that a business model with smaller contracts and a larger volume of customers would better serve the marketplace and steady the large swings in revenues for the segment.

BodyCells

We are continuing to pursue other growth opportunities by acquisition or internal growth. The development of BodyCells, which is anticipated to facilitate the collecting, processing and preserving of peripheral blood and adipose tissue stem cells allowing individuals to privately preserve their stem cells for potential future use in stem cell therapy, is currently suspended pending the identification of an alternative lab to partner.

Results of Operations for the Nine-Months Ended September 30, 2008

For the nine months ended September 30, 2008, our total revenue decreased approximately $2.4 million, or 42% to $3.3 million. Rain’s revenues decreased approximately $1.9 million, or 73%, due to a change in the business model.  Rain is focused on creating an annuity base business with high volume advertising.  Historically, Rain was reliant on a few large advertising contracts, and the risks associated with those.  Understanding that it would be difficult to value a few contracts, Rain made a decision in December of 2007 to focus on low cost, high volume, annuity based advertising.  The result in this change for the first nine months was a loss in revenue.  Cord’s revenues decreased $0.5 million or 15%, to $2.6 million, because of significant cutbacks in marketing and advertising.  Cord remains focused on strategic organic growth and accretive acquisition strategies, which will limit the losses and negative cash flow.  

Cost of services decreased 43% or by $1.1 million as a result of lower revenues, but Gross Profit increased from 35% of revenues to 54% due to a significantly higher proportion of revenues coming from the higher margin Cord business. The Company anticipates that through the continued growth and expansion of its Cord business, they will increasingly benefit from economies of scale in that business segment.

Administrative and selling expenses decreased by approximately $0.8 million or 23% from the prior comparative period to $2.8 million. The Company reduced its expenses across the board, due to cash restrictions.  The Company has had to raise additional debt to finance both its acquisitions as well as its operating losses. In addition, these financings resulted in a change in the Company’s derivative liabilities. Consequently, interest, financing costs and changes in derivative liabilities increased from $2.9 million to $4.3 million. All interest charges during the period have been accrued.

Our net loss increased by $1.1 million, or 28% from the prior comparative period.

Results of Operations for the Three-Months Ended September 30, 2008

For the three months ended September 30, 2008, our total revenue decreased approximately $0.7 million, or 44% to approximately $0.9 million. Rain’s revenues decreased approximately $0.4 million, or 84%, due to a change in the business model.  Rain is focused

15

on creating an annuity base business with high volume advertising.  Historically, Rain was reliant on a few large advertising contracts, and the risks associated with those.  Understanding that it would be difficult to value a few contracts, Rain made a decision in December of 2007 to focus on low cost, high volume, annuity based advertising.  The result in this change for this three-month period was a loss in revenue.  Cord’s revenues decreased $0.4 million, or 30%, to approximately $0.8 million, because of significant cutbacks in marketing and advertising.  Cord remains focused on strategic organic growth and accretive acquisition strategies, which will limit the losses and negative cash flow.  

Cost of services decreased 32 % or by $0.2 million as a result of the lower revenues. The Company anticipates that through the continued growth and expansion of its Cord business, they will increasingly benefit from economies of scale in that business segment.

Administrative and selling expenses decreased by approximately $0.1 million or 11% from the prior comparative period to approximately $1.0 million.  The Company has had to raise additional debt to finance both its acquisitions as well as its operating losses. In addition, these financings resulted in a change in the Company’s derivative liabilities. Consequently, interest, financing costs and changes in derivative liabilities increased from $1.0 million to $1.1 million. All interest charges during the period have been accrued.

Our net loss increased by $0.5 million, or 45 % from the prior comparative period

Liquidity and Capital Resources

We have experienced net losses of $5.4 million and $4.2 million for the nine months ended September 30, 2008 and 2007, respectively. At September 30, 2008, we had $56,599 in cash. We currently collect cash receipts from operations through both of our subsidiaries: Cord and Rain. Cord's cash flows from operations are not currently sufficient to fund operations in combination with its corporate expenses. Because of this shortfall, we have had to obtain additional capital through other sources as discussed in Note 4, Notes and Loans Payable.

Since inception, we have financed cash flow requirements through the issuance of common stock and warrants for cash, services and loans. As we expand our operational activities, we may continue to experience net negative cash flows

from operations and we will be required to obtain additional financing to fund operations through equity offerings and borrowings to the extent necessary to provide working capital. Financing may not be available, and, if available, it may not be available on acceptable terms. Should we secure such financing, it could have a negative impact on our financial condition and our shareholders. The sale of debt would, among other things, adversely impact our balance sheet, increase our expenses and increase our cash flow requirements. The sale of equity would, among other things, result in dilution to our shareholders. If our cash flows from operations are significantly less than projected, then we would either need to cut back on our budgeted spending, look to outside sources for additional funding or a combination of the two. If we are unable to access sufficient funds when needed, obtain additional external funding or generate sufficient revenue from the sale of our products, we could be forced to curtail or possibly cease operations. On June 27, 2008, we entered into a Securities Purchase Agreement with Tangiers Investors, LP whereby Tangiers may purchase up to $4 million of the Company’s common stock. CBAI has filed a Registration Statement on Form S-1 to register a portion of the shares issuable pursuant to the Securities Purchase Agreement. The registration statement was declared effective on November 4, 2008.

16

ITEM 4T.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

It is management's responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Company’s management, including the principal executive officer, the principal operations officer, and the principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2008.  Following this review and evaluation, management collectively determined that our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to management, including our chief executive officer, our chief operations officer, and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure. We are continuing our efforts in these regards in order to fully remedy previously reported material weaknesses and to ensure that all of our controls and procedures are adequate and effective. The Company filed a Registration Statement on Form S-1 to register a portion of the shares issuable pursuant to a Securities Purchase Agreement as discussed above. The registration statement was declared effective on November 4, 2008.  We are hoping to raise some additional capital to hire the necessary staff to address the material weaknesses disclosed in our latest Form 10KSB/A.

Changes in Internal Control over Financial Reporting

We assessed the effectiveness of our internal control over financial reporting as of December 31, 2007. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework.

Based upon management’s assessment using the criteria contained in COSO, and for the reasons discussed below, our management has concluded that, as of December 31, 2007, our internal control over financial reporting was not effective.

There were no significant changes in the Company's internal controls over financial reporting or in other factors during the nine months ended September 30, 2008 that could significantly affect these internal controls subsequent to the date of their most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.  We are continuing our efforts in these regards in order to fully remedy previously reported material weaknesses and to ensure that all of our controls and procedures are adequate and effective. Any failure to implement and maintain improvements in the controls over our financial reporting could cause us to fail to meet our reporting obligations under the SEC’s rules and regulations. The Company filed a Registration Statement on Form S-1 to register a portion of the shares issuable pursuant to a Securities Purchase Agreement as discussed above. The registration statement was declared effective on November 4, 2008. We are hoping to raise some additional capital to hire the necessary staff. Any failure to improve our internal controls to address the weaknesses we have identified could also cause investors to lose confidence in our reported financial information, which could have a negative impact on the trading price of our common stock. It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

17

PART II. - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

NONE

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

We have issued the following securities in the three months ended September 30, 2008 without registering them under the Securities Act of 1933:

2,000,000 common shares issued to the Company’s management on July 17, 2008; and  3,731,343 on September 2, 2008 in exchange for a reduction in an outstanding debenture.

Unless otherwise noted in this section, with respect to the sale of unregistered securities referenced above, all transactions were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended (the "1933 Act"), and Regulation D promulgated under the 1933 Act. In each instance, the purchaser had access to sufficient information regarding CBAI so as to make an informed investment decision. More specifically, we had a reasonable basis to believe that each purchaser was an "accredited investor" as defined in Regulation D of the 1933 Act and otherwise had the requisite sophistication to make an investment in CBAI's securities.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

NONE

ITEM 4.

SUBMISSION OF MATTERS TO A VOTE OF SECURITIES HOLDERS

NONE

ITEM 5.

OTHER INFORMATION

NONE

ITEM 6.

EXHIBITS AND REPORTS ON FORM 8-K

         (a)      Exhibits

         The following exhibits are filed as part of this Form 10-QSB.

31.1	Certification of the registrant's Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2	Certification of the registrant's Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1	Certification of the Company's Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)

18

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:    November 13, 2008

CORD BLOOD AMERICA, INC.
By:	/s/ MATTHEW L. SCHISSLER
	Matthew L. Schissler,
	Chairman and Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

19